Simplify Logo

Full-Time

Associate Director

Commercial Analytics

Posted on 6/3/2024

Syndax

Syndax

201-500 employees

Develops cancer therapies and conducts clinical trials

Biotechnology
Healthcare

Senior

Remote in USA

Category
Business Research
Business & Strategy
Required Skills
Python
Communications
SQL
Marketing
Data Analysis
Requirements
  • Bachelor’s degree
  • 6+ years of experience in pharma/biotech space in advanced analytics
  • Previous oncology experience
  • Experience with SAS, R, Python, or SQL
  • Experience with big data technology such as Hadoop
  • Knowledge of secondary data sources
  • Proficiency in manipulating and extracting insights from large data sources
  • Experience with field force analytics
  • Strong organizational skills
  • Strong interpersonal skills
  • Excellent oral and written communication skills
Responsibilities
  • Provide analytics support and recommendations to senior leadership and cross functional partners
  • Interpret key business reports providing business insights
  • Monitor performance and identify analytics opportunities
  • Employ new data sources and methodologies to uncover insights
  • Define and structure analysis to create the brand story
  • Synthesize multiple reporting, analyses, and data sources
  • Support marketing-mix models and lead digital & omni-channel analytics
  • Provide real-time analytics support to Commercial teams
  • Identify solutions to field needs and interact with field and home office personnel

Syndax Pharmaceuticals develops and commercializes therapies specifically for cancer patients, focusing on challenging cases like hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company conducts research and clinical trials to test the safety and effectiveness of its drugs, aiming to bring them to market after receiving regulatory approval. Syndax's main product, Entinostat, is currently in trials combined with Exemestane for treating HR+, HER2- breast cancer. Unlike many competitors, Syndax emphasizes targeting underserved patient populations and relies on strategic partnerships and public offerings to fund its research and development. The goal is to advance cancer treatment by providing new therapies that address significant medical needs.

Company Stage

IPO

Total Funding

$759.5M

Headquarters

Waltham, Massachusetts

Founded

2005

Growth & Insights
Headcount

6 month growth

30%

1 year growth

51%

2 year growth

167%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive clinical trial results for revumenib in combination therapies suggest strong potential for regulatory approval and market success.
  • The appointment of experienced professionals like Aleksandra Rizo to the board of directors enhances the company's strategic direction and clinical development capabilities.
  • Syndax's inducement grants and stock options for new employees indicate a commitment to attracting and retaining top talent, fostering a culture of innovation.

What critics are saying

  • The highly competitive oncology market requires continuous innovation and successful clinical trials to maintain a competitive edge.
  • Dependence on the success of key products like Entinostat and revumenib means that any setbacks in clinical trials or regulatory approvals could significantly impact the company's growth.

What makes Syndax unique

  • Syndax focuses on developing therapies for difficult-to-treat cancers, particularly HR+, HER2- breast cancer, setting it apart from competitors with broader oncology portfolios.
  • The company's flagship product, Entinostat, and its innovative pipeline, including revumenib and axatilimab, highlight its commitment to targeting specific cancer pathways and patient populations.
  • Syndax's strategic capital raises and public offerings provide robust financial support for its R&D efforts, unlike competitors who may struggle with funding.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE